MiNK Therapeutics EPS INKT

Diluted earnings per share by quarter and over the last twelve months, from 2020.

MiNK Therapeutics' earnings per share was −$2.40 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.62.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.62	n/a	−$2.40
Q1 FY26	Mar 31, 2026	−$0.57	n/a	−$2.84
Q4 FY25	Dec 31, 2025	−$0.56	n/a	−$2.97
Q3 FY25	Sep 30, 2025	−$0.65	n/a	−$3.03
Q2 FY25	Jun 30, 2025	−$1.06	n/a	−$2.84
Q1 FY25	Mar 31, 2025	−$0.70	n/a	−$2.51
Q4 FY24	Dec 31, 2024	−$0.62	n/a	−$2.91
Q3 FY24	Sep 30, 2024	−$0.46	n/a	−$3.89
Q2 FY24	Jun 30, 2024	−$0.73	n/a	−$4.93
Q1 FY24	Mar 31, 2024	−$1.10	n/a	−$6.00
Q4 FY23	Dec 31, 2023	−$1.60	n/a	−$6.60
Q3 FY23	Sep 30, 2023	−$1.50	n/a	−$7.30

Companies in Healthcare nearest MiNK Therapeutics' size, closest first, today.

Company	EPS, 12 months	Growth
INKTMiNK Therapeutics	−$2.40
APTAlpha Pro Tech	$0.41	+24% a year
ATNMActinium Pharmaceuticals	$0.36
SPROSpero Therapeutics	$0.11
LFVNLifevantage	$0.40	−46% a year
NEPHNephros	$0.16	+33% a year
ICCCImmucell	$0.08	−58% a year
KEQUKewaunee Scientific	$2.76	−33% a year
PDEXPro DEX	$4.11	+52% a year
PLXProtalix BioTherapeutics	$0.23	+283% a year
NATRNatures Sunshine Products	$1.01	+36% a year
Peer median	$0.38